RxDoctor Payments Data

Melody Stone, MD

Dermatology · Saint Joseph, MONPI 1558337196

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,722 of the $9,106 with a category attached, or 62.8%. 26 manufacturers reported payments, led by LEO Pharma Inc. at 27.6% of the total. Reporting peaked in 2019 at $4,890 and has fallen 91.4% since, to $420 in 2025.

$9,106in general payments, 2019–2025

Across 304 payments — averaging $29.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • LEO Pharma Inc.$3K
  • Pfizer$2K
  • AbbVie$1K
  • Sun Pharmaceutical Industries Inc.$558
  • Johnson & Johnson$536
  • E.r. Squibb & Sons, L.L.C.$316
  • plus $2K from 20 others
$4,284,455in research payments, 2019–2025

Across 1,148 payments — averaging $3732.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$843K
  • AbbVie$611K
  • Eli Lilly$552K
  • Incyte Corporation$493K
  • Pfizer$390K
  • Janssen Research & Development, LLC$274K
  • plus $1.1M from 23 others

What the payments were for

  • Consulting fees$2,33626%
  • Travel & lodging$97311%
  • Food & beverage$5,72263%
  • Education$751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,106 in reported general payments places this provider in the 75th percentile of 263 dermatology providers in Missouri.

See all dermatology providers in Missouri

Medicare billing

Part B allowed, 2024
$788,058
Medicare patients
1,334
Services billed
7,846

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ketoconazole281$7,003
Fluorouracil24$1,853
Metronidazole33$1,681
Clobetasol Propionate50$1,630
Doxycycline Hyclate70$1,332
Betamethasone Valerate26$1,193
Desonide13$735
Ciclopirox19$713
Mometasone Furoate41$664
Betamethasone Dipropionate14$469
Fluticasone Propionate12$295
Triamcinolone Acetonide30$161
Cephalexin29$160
Minoxidil14$119
Prednisone30$117

Paid to pharmacies, not to this prescriber.

Other dermatology in Saint Joseph

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →